Isofluran

Quick links to important sections

Isofluran

Treatment option: Anesthesia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isofluran

What is Isofluran?

Isoflurane is a clear, colorless liquid at room temperature that is used as a general inhalation anesthetic. It belongs to a class of medications known as halogenated ethers. When administered through a specialized vaporizer, the liquid is converted into a gas that the patient breathes in to induce and maintain a state of general anesthesia.

Chemical Properties and Mechanism

Isoflurane is an isomer of enflurane and is chemically stable, requiring no preservatives or stabilizers. It is characterized by its high degree of physical stability and a pungent, ethereal odor.

In a clinical setting, isoflurane works by altering the activity of various proteins in the neuronal membranes of the central nervous system. This action results in a reversible loss of consciousness, a reduction in pain sensitivity, and a relaxation of skeletal muscles, allowing for the performance of surgical or diagnostic procedures.

Primary Characteristics

Isoflurane is known for several distinct properties within the field of anesthesiology:

  • Induction and Recovery: It provides a relatively rapid induction of anesthesia and a prompt recovery once administration is ceased, as it has low solubility in the blood.
  • Metabolism: The substance undergoes minimal metabolism within the body. The vast majority of the inhaled dose is exhaled unchanged through the lungs, which reduces the chemical load on the liver and kidneys.
  • Cardiovascular Effects: Like other agents in its class, it can cause a dose-dependent reduction in blood pressure and changes in heart rate.
  • Respiratory Effects: It acts as a respiratory depressant and a bronchodilator, which can influence the management of the airway during a procedure.

Clinical Application

Isoflurane is utilized across a wide range of surgical specialties. Because of its stability and predictable effects, it is often used for the maintenance phase of general anesthesia after induction has been achieved with other agents. It is frequently administered in combination with oxygen or a mixture of oxygen and nitrous oxide.

What side effects are possible with Isofluran?

Possible side effects and safety information

The safety profile of Isoflurane is categorized based on adverse reactions documented in official regulatory sources, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC). These effects are typically dose-dependent and are managed under controlled clinical conditions.


Frequency and System Classification

Adverse reactions are classified by frequency and by the system or organ class affected. Most Common (ge 5%) reactions reported include agitation, cough, nausea, vomiting, and shivering, often occurring during recovery from anesthesia. Common and expected effects related to the agent's primary action are dose-dependent hypotension (low blood pressure) and respiratory depression.

System-organ classes involved include Cardiac Disorders (e.g., arrhythmias, hypotension), Respiratory, Thoracic and Mediastinal Disorders (e.g., laryngospasm, respiratory depression), and Hepatobiliary Disorders (e.g., transient elevations in liver enzymes).


Serious Adverse Reactions and Safety Restrictions

Serious adverse reactions are rare but critically important. These include Malignant Hyperthermia (a rare, life-threatening syndrome) and Perioperative Hyperkalemia (elevated potassium levels) reported primarily in susceptible pediatric patients.

The medicine is contraindicated in individuals with a known or suspected genetic susceptibility to Malignant Hyperthermia and in those with a history of unexplained hepatic dysfunction following prior exposure to halogenated anesthetics.


Population-Specific Safety Notes

Specific considerations apply to certain groups. In pediatric patients, there is a higher incidence of upper airway adverse events during induction. In obstetrics, the agent is noted to cause uterine relaxation, which may increase blood loss. The required dose is lower for geriatric patients due to age-related physiological changes.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdosage with Isoflurane, typically resulting from an excessively high concentration of the volatile agent, is officially documented as presenting with excessive deepening of anesthesia and severe systemic effects. The primary manifestations listed in regulatory information include profound respiratory depression, which can lead to apnea, and severe hypotension (significant decrease in blood pressure).

Severe overdosage can rapidly progress to life-threatening outcomes, including severe circulatory depression and potential cardiac arrest. The official labeling also notes the risk of triggering Malignant Hyperthermia in susceptible individuals and warns of rare cases of perioperative hyperkalemia in pediatric patients.

Required Emergency Actions

Urgent professional medical assistance must be sought immediately upon any sign of overdosage or severe physiological change. Regulatory documents mandate the following actions:

  • The administration of Isoflurane must be discontinued immediately.
  • A patent airway must be established, and respiration must be assisted or controlled, typically by administering mathbf100% oxygen.
  • Management relies on symptomatic and supportive treatment, as no specific antidote is known for Isoflurane overdose.

Interventions focus on maintaining cardiovascular function and continuous monitoring until the patient stabilizes.

Therapeutic Uses of Isofluran

What Isoflurane Treats: Main Uses and Benefits

Isoflurane is generally categorized as a volatile anesthetic agent with the primary therapeutic domain of inducing and maintaining general anesthesia. This anesthetic state creates a controlled, reversible loss of consciousness, pain perception (analgesia), and muscle activity, which is often necessary for invasive or complex procedures. Isoflurane may be used for both the initial induction of the anesthetic state and its subsequent maintenance throughout the surgical intervention.

This application is highly relevant in clinical settings that involve acute or unstable symptom patterns, as it is applied in addressing symptoms related to heightened physiological activity. A core functional benefit may assist with the ability to produce necessary adjustments in the anesthetic state, which assists with maintaining functional stability during an operation. Overall, this volatile agent contributes to easing the overall symptom burden by providing muscle relaxation that helps with functional stability.

The agent is used for managing symptom clusters that may become intense or disruptive and is commonly applied in addressing the need for unconsciousness, analgesia, and muscle relaxation during procedures. This therapy may help maintain a sense of stability when symptoms become more noticeable, particularly in contexts involving heightened systemic burden. This volatile agent is commonly used to help with conditions associated with acute or disruptive episodes where short-term symptomatic assistance is needed.


Quick Fact: Focus on Symptom clusters that may become intense or disruptive

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Patients of all ages (adult, older adult, and pediatric) for the maintenance of general anesthesia during surgery. Use is also documented for obstetric procedures (labor and delivery) to achieve uterine relaxation.
Populations for whom use is contraindicated Patients with a known or suspected genetic susceptibility to malignant hyperthermia (MH). Patients with a known sensitivity to Isoflurane or other halogenated agents. Individuals with a history of confirmed hepatitis or unexplained severe hepatic dysfunction following exposure to this class of anesthetics.
Age-related eligibility rules Approved for the maintenance phase in pediatric patients. Use is not recommended for the induction of anesthesia in infants and children due to the potential for adverse respiratory events. Older adults are eligible but typically require lower anesthetic concentrations.
Condition-specific eligibility rules Use requires caution and close monitoring in patients with Coronary Artery Disease (CAD) or a predisposition to increased intracranial pressure (ICP). Caution is also noted for patients with certain neuromuscular disorders.

Eligibility Classifications

Category Official Regulatory Classification
Eligibility severity classification Contraindicated (for MH susceptibility, hypersensitivity, and history of severe liver injury); Not Recommended (for pediatric induction); Caution/Conditional Use (for CAD, increased ICP).
Eligibility-context constraints Eligibility is constrained by genetic/historical factors (MH, prior hepatic injury) and phase-of-use (pediatric induction restriction).

Resulting Eligibility Structure

Official eligibility statements indicate that use is prohibited in patients with a genetic risk of malignant hyperthermia or certain historical adverse liver reactions to halogenated anesthetics. For all other eligible groups, Isoflurane is approved for the maintenance phase across all ages. However, regulators advise against its use during the induction phase in young children. Conditional use applies to patients with specific cardiac or neurological conditions, requiring careful administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Isoflurane's interactions is structured primarily around pharmacodynamic enhancement and effects on anesthetic requirements, rather than metabolic enzyme pathways.

Pharmacodynamic and Anesthetic-Modifying Interactions

Co-administration with nondepolarizing neuromuscular blocking agents results in a clinically significant potentiation of muscle blockade. Agents such as Opioids and Nitrous Oxide ( N2 O) formally cause a decrease in the Minimum Alveolar Concentration (MAC) of Isoflurane needed to maintain anesthesia. Additionally, co-use with cardiovascular agents like Beta Blockers or Calcium Antagonists may lead to the exacerbation of cardiovascular effects, including clinically notable hypotension.

Product-Specific and Population Constraints

Isoflurane vapor interacts with desiccated carbon dioxide ( CO2) absorbents used in the administration circuit, leading to the generation of carbon monoxide and elevated carboxyhemoglobin levels in the patient. Regarding specific populations, the co-administration of inhaled anesthetics and succinylcholine has been associated with perioperative hyperkalemia in vulnerable pediatric patients with latent neuromuscular disease. Chronic alcohol abuse is also noted as a factor that increases the required MAC of Isoflurane.

Mechanism of Action

How Isoflurane Works

Isoflurane modulates neuronal activity primarily within the central nervous system (CNS) and spinal cord through the simultaneous engagement of multiple molecular targets.

Potentiation of Inhibitory Neurotransmission

The agent acts as a positive allosteric modulator of the gamma-aminobutyric acid type A ( GABA A) receptors, the main inhibitory receptors in the CNS. This interaction amplifies the effect of GABA, promoting increased influx of chloride ions ( Cl^-) across the neuronal membrane. This mechanistic cascade results in neuronal hyperpolarization, which decreases the neuronal discharge rate and overall excitability.

Inhibition of Excitatory Signaling

Isoflurane concurrently modulates targets to decrease membrane depolarization. It functions as an inhibitor of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors and enhances activity at glycine receptors in the spinal cord. Modifying these pathways contributes to a regulated state of synaptic activity, which decreases motor neuron activity.

Modulation of Ion Channels

Additionally, isoflurane influences cellular excitability by inhibiting neuronal voltage-gated sodium ( Na^+) channels and certain potassium ( K^+) channels. These combined effects modify early molecular steps that influence neuronal communication by reducing the likelihood of action potential generation.

Dosage and Administration Information

How to Use Isoflurane

Isoflurane is a volatile agent used exclusively for the induction and maintenance of general anesthesia in a controlled medical environment. Its administration is structured by strict protocols.


Administration Scope

Feature Usage Guideline
Route of Administration Inhalation (administered as a vapor).
Equipment Requirement Must be delivered using a calibrated vaporizer specifically designated for Isoflurane to ensure precise control over the inspired concentration.
Professional Supervision Administration must be performed only by persons trained in general anesthesia in a setting equipped for circulatory and respiratory support.

Dosing Patterns and Adjustments

Dosage is always individualized and continuously titrated throughout the procedure to achieve the desired effect. The concentration is adjusted by the professional based on the patient's immediate response.

  • Induction: Inspired concentrations typically range from 1.5% to 3.0% to quickly establish the anesthetic state.
  • Maintenance: Sustained concentrations generally range from 1.0% to 3.5%, depending on whether nitrous oxide is co-administered with oxygen.
  • Age-Related Dosing: The required dose decreases with increasing patient age; concentrations must be adjusted downward for older adults and children to prevent excessive effects.

These instructions define a continuous, dynamic administration protocol that requires constant expert management and specialized equipment, reflecting the controlled nature of general anesthesia.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Isoflurane

This overview summarizes the research that has been conducted on Isoflurane, describing the types of studies performed, what they examined, and where scientific uncertainty remains. This information is intended for educational purposes only and is not medical advice. The details presented here are drawn only from clinical and non-clinical research reports and do not constitute recommendations for use.

Evidence for Use in Inducing and Maintaining General Anesthesia

Isoflurane was studied for its use in both starting (inducing) and keeping (maintaining) a state of general anesthesia during surgical procedures. Researchers primarily used short-term Randomized Controlled Trials (RCTs) and comparative clinical trials to explore what outcomes were measured. These studies monitored several physiological responses, including outcomes related to systemic or functional imbalance, such as changes in heart rate and blood pressure, as well as outcomes describing episodic or acute changes like the time it took for a patient to become unconscious and the time to fully wake up after the procedure.

Research measured changes during the study period related to the speed of anesthesia induction and emergence. Data from studies describe patterns related to the speed at which measured outcomes changed regarding the anesthetic state. These findings describe patterns observed in the studies regarding the monitoring of key physiological metrics while the patient was evaluated in the operating room setting.

Comparing Isoflurane to Other Anesthetics

Studies have explored how Isoflurane performs when measured directly against other inhaled agents (like Sevoflurane) or intravenous drugs used for anesthesia. These trials research examined differences in metrics such as the time to full recovery after surgery and the stability of the patient's breathing and circulation during the procedure.

Different patterns were observed in some studies when measured against other agents, particularly regarding the speed of emergence from anesthesia. Findings were mixed across this body of comparative research, and measured outcomes varied depending on the specific surgical procedure, other medications, and the measured dose. Studies add to the body of research by describing the use of these different anesthetic options across similar surgical settings.

Long-Term Studies and Extended Follow-up

Research has also been studied for whether there are effects that persist long after the patient has woken up from the anesthetic. These studies often include observational settings evaluating daily-life functioning or involve research on animal models to explore potential effects on the brain.

Evidence in Special Populations

Specific clinical trials was evaluated in certain patient subgroups, including pediatric patients (children and neonates) and geriatric patients (older adults). Research has also examined patients with certain underlying health issues, such as heart or lung conditions, to observe measured physiological changes.

What is Still Uncertain About Isoflurane Research

Despite the existing body of clinical research, several areas remain insufficiently understood. Certainty remains low for the long-term impact on neurological and cognitive function, especially following exposure in very young children. Comparative evidence is lacking for many new or specialized surgical techniques.

Key Studies & References

  1. Long-Term Effects of Neonatal Single or Multiple Isoflurane Exposures on Spatial Memory in Rats

Frequently Asked Questions (FAQ)

Common questions about Isofluran (FAQ)


Q: Are there different brand names for the drug Isofluran?

Isoflurane is the established generic name for this anesthetic. According to official drug information sources, the medicine may be marketed under various brand names, such as IsoSol. This is a common situation for medicines that have been approved and made available by multiple manufacturers.


Q: Is Isofluran usage restricted to only certain types of surgery?

Official prescribing information states that Isoflurane is indicated for the induction and maintenance of general anesthesia. Its primary purpose is tied to the requirement for general anesthesia during surgical procedures. The documentation does not describe restrictions based on specific surgical types.


Q: Are there any known issues with using Isofluran in people who have kidney problems?

Official regulatory documents list specific warnings related to prior liver (hepatic) dysfunction, which is a key contraindication. While occupational exposure guidelines have examined potential long-term effects on the kidneys, patient labeling does not typically list kidney dysfunction as a contraindication or common adverse reaction for therapeutic use.


Q: Do health regulators consider Isofluran a standard option for general anesthesia?

Yes, Isoflurane is recognized internationally as an important medicine. Official information indicates that it is included on the World Health Organization’s (WHO) Model List of Essential Medicines in the category for inhalational general anesthetics.


Q: What is the typical medical setting where Isofluran is used?

Isoflurane is a prescription inhalation liquid that must be administered under highly controlled conditions. According to regulatory documents, it is always given by a trained health professional in a controlled medical environment in a setting prepared for respiratory and circulatory support.


Q: Can Isofluran interact with common over-the-counter pain relievers?

Official drug labeling highlights interactions with major drug classes like opioids and cardiovascular agents. Although common over-the-counter pain relievers are not specifically listed, official sources describe the need for disclosure of all medicines, including non-prescription drugs, to the healthcare team before the procedure.


Q: Is Isofluran part of the World Health Organization's list of essential medicines?

Yes, Isoflurane is recognized as an essential medicine. Official information indicates that it is included on the World Health Organization’s (WHO) Model List of Essential Medicines.


Q: Do certain herbal supplements interact with Isofluran?

Official drug labeling addresses the need for the disclosure of all medicines and supplements prior to anesthesia. Some herbal products can affect bodily systems such as blood pressure or clotting, potentially altering the required anesthetic effect. Therefore, official sources describe the need for patients to share information about any herbal supplement use with their healthcare team.


Q: What are the general rules regarding driving after a procedure involving Isofluran?

General anesthesia reversibly affects the central nervous system, and these effects can persist temporarily afterward. Official product information describes that activities requiring mental alertness, such as driving or operating machinery, should be avoided for a period of at least 24 hours following the procedure, as cognitive effects may persist.


Q: What is the significance of the smell associated with Isofluran?

Official documentation describes Isoflurane as having a mildly pungent, ethereal odor. This smell is significant because it can sometimes cause irritation in the airway. For this reason, official sources advise caution or describe why its use is not recommended for the initial induction of anesthesia in infants and young children.


Q: Is Isofluran known to be a teratogen (cause birth defects) in studies?

Studies focusing on reproduction and development have been conducted using animal models. The evidence obtained from these studies did not show any signs of teratogenic activity, which means it was not found to cause birth defects at anesthetic concentrations.


Q: Can chronic smokers have issues with Isofluran?

Official warnings and precautions do not list chronic smoking as a contraindication to use. However, smoking can impact the patient's underlying lung function and potentially alter carbon monoxide levels in the blood. Therefore, the anesthesiologist may need to perform careful monitoring during the use of any inhaled anesthetic.


Q: Are patients required to fast before receiving Isofluran?

Yes, official preoperative protocols advise that fasting is a standard requirement before receiving any form of general anesthesia. This measure is necessary to help prevent the risk of aspiration of stomach contents into the lungs. Official protocols indicate that patients are to adhere to the specific fasting times for solids and liquids provided by the care team.


Q: Does the evidence support the use of Isofluran in veterinary medicine as well?

Yes, Isoflurane is used widely for general anesthesia in animals. The official drug label includes a caution that Federal law restricts the drug to be used by, or on the order of, a licensed veterinarian.


Q: Is Isofluran usage monitored by specific medical bodies?

Yes, the environment surrounding Isoflurane use is monitored by various bodies. Occupational health and safety organizations oversee its use to ensure worker exposure to waste anesthetic gas is controlled. Furthermore, the patient's physiological status during administration is continuously monitored by the anesthesiologist and specialized equipment.


Q: How does the body eliminate Isofluran after the procedure?

Isoflurane is known to be relatively insoluble in the bloodstream. Because of this physical property, the body primarily eliminates the drug very quickly through the lungs via exhalation once administration is stopped. Only a very small fraction of the drug is metabolized by the liver.


Q: Is it necessary to be intubated when receiving Isofluran?

The official administration guidelines require the procedure to be performed in a setting fully equipped for comprehensive respiratory support. While not an absolute requirement, intubation is a common procedure described as being used to securely maintain the airway during deep general anesthesia, particularly given the drug's effect on spontaneous respiration.

How should Isofluran be stored and disposed of?

How to Store and Dispose of Isoflurane

Isoflurane liquid must be stored according to regulatory requirements to ensure its stability and prevent accidental exposure.


Storage Requirements

  • Temperature: Store at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions [1, 2]. Protect from freezing and extreme heat [2, 5].
  • Security: Must be stored out of the sight and reach of children and kept in a secure, locked location [1, 5].
  • Stability: The product is a clear, colorless, stable liquid and does not require protection from light [3, 4]. Containers must be tightly closed [5].

Disposal

Disposal of unused contents and containers must follow federal, state, and local regulatory requirements for chemical hazardous waste [5]. A specific warning notes that the product can react with desiccated CO2 absorbents to produce carbon monoxide [6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isofluran found in:

A-Z Index: